Want to stay updated on the latest news?
Create a Reader Account today to follow the industries and companies that interest you, and customize your news dashboard. SIGN INTO READER ACCOUNT CREATE READER ACCOUNT
Alvotech Provides Update on Corporate Sustainability Framework
March 28, 2023 05:00 ET
|
Alvotech
Alvotech (Nasdaq: ALVO) (the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced an update to the...
Alvotech birtir nýjar upplýsingar um sjálfbærni og samfélagslega ábyrgð
March 28, 2023 05:00 ET
|
Alvotech
Alvotech hefur birt nýjar upplýsingar um sjálfbærni og samfélagslega ábyrgð, þar á meðal mælikvarða umhverfis-, samfélags- og stjórnarhátta (ESG) fyrir árið 2022. „Markmið okkar er að bæta aðgengi...
Alvotech Provides Update on Corporate Sustainability Framework
March 28, 2023 05:00 ET
|
Alvotech
REYKJAVIK, Iceland, March 28, 2023 (GLOBE NEWSWIRE) -- Alvotech (Nasdaq: ALVO) (the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for...
Alvotech to Present Clinical Study Data for AVT04, a Proposed Biosimilar to Stelara®, at 2023 American Academy of Dermatology (AAD) Annual Meeting
March 17, 2023 09:10 ET
|
Alvotech
Alvotech to present two posters related to pharmacokinetics and confirmatory clinical studies for AVT04 (ustekinumab), a proposed biosimilar to Stelara® Marketing applications for AVT04 have been...
Alvotech kynnir niðurstöður klínískra rannsókna á AVT04, fyrirhugaðri hliðstæðu við Stelara á ársþingi samtaka bandarískra húðsjúkdómalækna (AAD)
March 17, 2023 09:10 ET
|
Alvotech
Alvotech kynnir niðurstöður úr rannsókn á lyfjahvörfum og klínískri rannsókn á sjúklingum fyrir AVT04 (ustekinumab), fyrirhugaða líftæknilyfjahliðstæðu við StelaraUmsóknir um markaðsleyfi fyrir AVT04...
Alvotech to Present Clinical Study Data for AVT04, a Proposed Biosimilar to Stelara®, at 2023 American Academy of Dermatology (AAD) Annual Meeting
March 17, 2023 09:10 ET
|
Alvotech
Alvotech to present two posters related to pharmacokinetics and confirmatory clinical studies for AVT04 (ustekinumab), a proposed biosimilar to Stelara®Marketing applications for AVT04 have been...
Alvotech Reports Financial Results for Full Year 2022 and Provides Business Update
March 01, 2023 16:30 ET
|
Alvotech
Full year 2022 total revenue, including other income, increased by 114% to $85.0 million, compared to $39.7 million in 2021, driven by both milestone revenue and product revenue from commercialization...
Alvotech Reports Financial Results for Full Year 2022 and Provides Business Update
March 01, 2023 16:30 ET
|
Alvotech
Full year 2022 total revenue, including other income, increased by 114% to $85.0 million, compared to $39.7 million in 2021, driven by both milestone revenue and product revenue from commercialization...
Alvotech birtir uppgjör fyrir árið 2022 og kynnir nýjustu áfanga í rekstri félagsins
March 01, 2023 16:30 ET
|
Alvotech
Heildartekjur ársins 2022 hækkuðu um 114% í 85,0 milljónir dollara samanborið við 39,7 milljónir dollara á árinu 2021, vegna tekna af sölu AVT02, líftæknihliðstæðu við Humira®, sem komin er á markað í...
Alvotech Announces Webcast of 2022 Full Year Financial Results at 8:00 am ET on March 2, 2023
February 27, 2023 19:15 ET
|
Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results...